OTCM
RIBT
Market cap3kUSD
Dec 04, Last price
0.00USD
1D
0.00%
1Q
200.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
RiceBran Technologies
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
25.91%
Rev. gr., 5y
8.94%
Revenues
23m
-45.58%
Net income
-9m
L+14.21%
CFO
-2m
L-38.57%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
RiceBran Technologies, together with its subsidiaries, operates as a specialty ingredient company. It focuses on producing, processing, and marketing of value-added healthy, natural, and nutrient dense products derived from rice and other small grains. The company converts raw rice bran into stabilized rice bran (SRB) and high value derivative products, including RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a nutritious carbohydrate and lipid rich fraction of RiBalance; RiFiber, a protein and fiber rich insoluble derivative of RiBalance; and ProRyza products, which includes derivatives composed of protein and protein/fiber blends. Its SRB and derivative products are nutritional and beneficial food products that contain a combination of oil, protein, carbohydrates, vitamins, minerals, fibers, and antioxidants that enhance the nutritional value of consumer products. The company's SRB products are also marketed as feed ingredients in the animal nutrition markets. It serves food and animal nutrition manufacturers, wholesalers, and retailers in the United States and internationally. The company was formerly known as NutraCea and changed its name to RiceBran Technologies in October 2012. RiceBran Technologies was founded in 2000 and is headquartered in Tomball, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||